Acupoint Catgut Embedding With Laser Acupuncture for Weight Loss in Adults With Obesity

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-65
SponsorTaipei City Hospital

About this trial

Acupoint catgut embedding and laser acupuncture have each been studied as treatments for obesity in adults, but the two have not been evaluated in combination, and few trials have measured anthropometric, biochemical, and blood pressure outcomes together.

This single-center randomized sham-controlled trial plans to enroll 120 adults aged 20 to 65 years with obesity. All participants receive the same acupoint catgut embedding with poliglecaprone 25 absorbable suture at 15 acupoints, comprising 25 insertions, once every 2 weeks for 6 sessions over 12 weeks. Participants are randomly assigned in a 1:1 ratio to receive, immediately before each embedding session, either active 810 nm laser acupuncture or sham laser acupuncture delivered with a device that is identical in appearance, indicator light, and operating sound but emits no therapeutic energy. Both groups also receive standardized dietary and exercise counseling.

Because the acupoint embedding regimen is identical in both groups and the groups differ only in whether the laser emits energy, the comparison estimates the incremental effect of laser acupuncture added to acupoint embedding. Participants are treated for 12 weeks and then followed for a further 12 weeks, to Week 24.

Eligibility criteria

Qualifiers

Age 20 to 65 years

Body mass index of 27 kg/m² or greater, or body mass index of 24 kg/m² or greater together with a waist circumference of 90 cm or greater in men or 80 cm or greater in women

Able to fully understand the informed consent document and willing to give written informed consent

No use of weight-loss medication and no other weight-reduction treatment in the 3 months before enrollment

Disqualifiers

Current use of medication that may affect body weight, including corticosteroids, antipsychotics, insulin, or glucagon-like peptide-1 (GLP-1) receptor agonists

Known secondary cause of obesity, such as hypothyroidism, Cushing syndrome, or pituitary disease

Severe cardiovascular, hepatic, or renal disease, or poorly controlled diabetes defined as glycated hemoglobin (HbA1c) above 9 percent

Currently pregnant, breastfeeding, or planning pregnancy within 6 months

Trial design

Treatments tested in this trial

  • Acupoint catgut embedding
  • Active laser acupuncture
  • Sham laser acupuncture
  • Dietary and exercise counseling

Treatment groups

120 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Taipei City Hospital

Lead sponsor

Taipei City Government Department of Health

Collaborator